Combined Therapy of biespecu00cdficos Antibodies specific for FAP (Protein Activator of Human fibroblasts) and DR5 (Death receptor 5) and quimioterapu00c9uticos agents

摘要

Combination Therapies using these Antibodies biespecu00edficos and a chemotherapeutic Agent, and the use of these Combination Therapies for the treatment of cancer.Claim 1: an Antibody that binds to the biespecu00edfico Death receptor 5 (DR5) and Fibroblast Activation Protein (FAP) comprising at least one binding site for DR5 specific antigen and at least one binding site for FAP specific antigen for use as ter Apia in a combined method to treat cancerIn the biespecu00edfico Antibody is used in combination with a chemotherapeutic Agent doxorubicin selected between irinotecan, oxaliplatin, 5-fu, an inhibitor of MDM2, an inhibitor of bcl-2, Abraxane, paclitaxel, gemcitabine, bortezomib, cyclopamine, an inhibitor of PARP, ifosfamide Or an anti VEGF Antibody.Claim: The biespecu00edfico 18 Antibody that binds to the death receptor 5 (DR5) and Fibroblast Activation Protein (FAP) in combination with a chemotherapeutic agent for use in the method of treatment of any one of claims 1 to 17,The specific antigen binding site for FAP consists of: (a) a complementarity Determining Region 3 (CDR1) heavy chain SEC ID no. 9; (b) a complementarity Determining Region 2 (CDR2) heavy chain SEC ID no. 10; (c) Determining Region L Complementarity 3 (CDr3) heavy chain SEC ID no. 11; (d) a complementary Determining Region1 Variety (CDR1) light chain SEC ID no. 12; (e) a complementarity Determining Region 2 (CDR2) light chain SEC ID no. 13; and (f) a complementarity Determining Region 3 (CDr3) light chain SEC ID no. 14.